Targeting the NOTCH pathway with gamma-secretase inhibitors may increase the efficacy of osimertinib in non-small-cell lung cancer.670 Targeting antiapoptotic proteins, such as survivin (BIRC5) in combination with EGFR-inhibitors, may also be a therapeutic opportunity in the future.661 In the case of RCC, hypoxia-mediated changes play an important role in the development of resistance. Here, EGFR is linked to non-small cell lung carcinoma.